Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ASND

Ascendis Pharma A/S

May 29 • 04:00PM ET

224.11

-13.36 -5.63 %

Healthcare • Biotechnology • Denmark • Large • NASD

May 29, 11:01 AMITC brief supporting BioMarin patent claims against ASND sparks 7% decline

Peers: BMRN VRTX IONS REGN ALNY EXEL INCY RARE CRSP NBIX

| Held by: TCAF IBB SQS SPDW FDG AFOS QQQJ MSSM MEDI TMSL

Index	-	P/E	25.26	EPS (ttm)	8.87	Insider Own	0.89%	Shs Outstand	62.11M	Perf Week	-9.45%
Market Cap	13.92B	Forward P/E	20.56	EPS next Y	10.90	Insider Trans	-3.33%	Shs Float	61.56M	Perf Month	1.74%
Enterprise Value	14.29B	PEG	-	EPS next Q	1.82	Inst Own	107.99%	Short Float	2.80%	Perf Quarter	-4.02%
Income	581.90M	P/S	13.85	EPS this Y	455.41%	Inst Trans	-45.97%	Short Ratio	2.64	Perf Half Y	8.45%
Sales	1.01B	P/B	24.76	EPS next Y	-29.99%	ROA	33.69%	Short Interest	1.72M	Perf YTD	5.10%
Book/sh	9.05	P/C	21.09	EPS next 5Y	-	ROE	325.80%	52W High	250.74 -10.62%	Perf Year	37.01%
Cash/sh	10.63	P/FCF	275.25	EPS past 3/5Y	27.03% 14.76%	ROIC	57.78%	52W Low	158.16 41.70%	Perf 3Y	149.70%
Dividend Est.	-	EV/EBITDA	1057.93	Sales past 3/5Y	147.23% 152.45%	Gross Margin	87.35%	Volatility	3.87% 4.14%	Perf 5Y	66.77%
Dividend TTM	-	EV/Sales	14.22	EPS Y/Y TTM	249.36%	Oper. Margin	-0.66%	ATR (14)	9.38	Perf 10Y	1501.93%
Dividend Ex-Date	-	Quick Ratio	0.72	Sales Y/Y TTM	155.14%	Profit Margin	57.88%	RSI (14)	40.43	Recom	1.05
Dividend Gr. 3/5Y	- -	Current Ratio	1.00	EPS Q/Q	787.72%	SMA20	-5.63%	Beta	0.41	Target Price	293.62
Payout	-	Debt/Eq	1.84	Sales Q/Q	171.53%	SMA50	-3.82%	Rel Volume	1.94	Prev Close	237.47
Employees	-	LT Debt/Eq	0.79	Earnings	May 07 BMO	SMA200	3.70%	Avg Volume	651.68K	Price	224.11
IPO	Jan 28, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	5921.98% -7.60%	Trades		Volume	1,266,008	Change	-5.63%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-26	Initiated	Citigroup	Buy	$355
Mar-16-26	Resumed	Jefferies	Buy
Jan-28-26	Initiated	Barclays	Overweight	$342
Nov-18-25	Initiated	Wolfe Research	Peer Perform	$255
Oct-17-25	Initiated	Raymond James	Strong Buy	$271
Jul-03-25	Resumed	Morgan Stanley	Overweight	$250
May-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$250
Apr-16-25	Initiated	RBC Capital Mkts	Outperform	$205
Jan-07-25	Initiated	UBS	Buy	$196
Sep-05-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jun-25-24	Upgrade	TD Cowen	Hold → Buy	$156 → $175
May-31-24	Initiated	Stifel	Buy	$200
Dec-20-23	Initiated	Jefferies	Buy	$150
Jun-14-23	Resumed	Credit Suisse	Neutral	$89
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$151 → $108
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy	$174
Aug-30-22	Resumed	Berenberg	Buy	$166
Mar-28-22	Resumed	Wedbush	Outperform	$163

Show Previous Ratings

May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com) -5.63%
May-20-26 03:29PM	JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms (Investing.com)
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
May-07-26 07:30AM	Ascendis Pharma Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 04:01PM	New 2-Year Data from Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged =5 Years (GlobeNewswire)
04:01PM	Loading…
Apr-30-26 04:01PM	Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 (GlobeNewswire)
Apr-21-26 04:31PM	Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 (GlobeNewswire)
Apr-20-26 08:00AM	Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq (GlobeNewswire)
Apr-08-26 12:00PM	Ascendis Pharma to List Ordinary Shares Directly on Nasdaq (GlobeNewswire) +5.77%
08:01AM	New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon hGH Accelerated TransCon CNP's Benefits Beyond Linear Growth in Children with Achondroplasia (GlobeNewswire)
Apr-06-26 04:01PM	Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL (Navepegritide) in the United States (GlobeNewswire)
Mar-17-26 08:30AM	New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 (GlobeNewswire)
Mar-16-26 08:00AM	New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 (GlobeNewswire)
Mar-04-26 10:32PM	Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference (MarketBeat)
09:54PM	Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia (MarketBeat)
01:24PM	Loading…
01:24PM	This Biopharma Stock Flirts With Buy Point After New FDA Approval (Investor's Business Daily)
05:45AM	Ascendis Wins FDA Approval For Rare Disease Therapy (Benzinga)
Mar-02-26 08:43AM	Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
08:02AM	Ascendis Wins FDA Approval For Rare Disease Therapy (Benzinga)
07:22AM	Ascendis wins FDA approval of dwarfism drug (BioPharma Dive)
Feb-27-26 05:57PM	FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older (GlobeNewswire)
Feb-20-26 04:10AM	Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth (Insider Monkey)
Feb-12-26 12:44PM	BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 (Benzinga)
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
12:03AM	Ascendis Pharma AS (ASND) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-11-26 06:39PM	Ascendis Pharma A/S Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-04-26 04:01PM	Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 (GlobeNewswire)
Jan-30-26 02:07AM	RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets (Insider Monkey)
Jan-29-26 03:01PM	BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT (Insider Monkey)
10:14AM	Loading…
Jan-26-26 10:14AM	Allstate Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Jan-15-26 01:03PM	Ascendis Pharma A/S (ASND): A Bull Case Theory (Insider Monkey)
Jan-14-26 06:14AM	Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains? (Zacks)
Jan-12-26 07:02PM	Ascendis Pharma A/S Touts 683M Product Revenue, Feb PDUFA Catalyst at JPM Healthcare Conference (MarketBeat)
Jan-09-26 06:01PM	Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-26 11:03PM	Ascendis Pharma COACH Week 52 data show combo TransCon CNP + hGH boosts growth in achondroplasia (MarketBeat)
04:01PM	Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) (GlobeNewswire)
Jan-05-26 08:30AM	Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 09:42AM	Ford Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Dec-11-25 10:37AM	Eight stock picks to play one of the healthiest corners of the market (MarketWatch)
Dec-04-25 11:10AM	The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. (Barrons.com)
Nov-26-25 05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
Nov-25-25 06:15PM	Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia (GlobeNewswire)
Nov-17-25 04:01PM	Results of Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics (GlobeNewswire) +5.95%
Nov-13-25 12:00AM	Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-12-25 04:01PM	Ascendis Pharma Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:54AM	MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth (Zacks)
05:25AM	Cisco Systems headlines earnings slate (MarketWatch)
03:51AM	Stock Market Today: Dow consolidates after 3-day 1,000-point surge to record high, S&P 500 and Nasdaq called higher as Treasury yields dip; Cisco earnings on tap. (MarketWatch)
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks)
Nov-07-25 08:30AM	New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism (GlobeNewswire)
Nov-05-25 04:01PM	Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 (GlobeNewswire) -5.04%
Nov-03-25 04:01PM	3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 (GlobeNewswire)
Oct-13-25 12:29PM	Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Oct-08-25 04:01PM	Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon CNP for Treatment of Children with Achondroplasia (GlobeNewswire)
Oct-07-25 09:40AM	Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Oct-02-25 01:35AM	UBS Maintains Buy on Ascendis (ASND), Sees Upside from Yorvipath Data (Insider Monkey)
Sep-24-25 02:12AM	Bank of America Securities Reiterates a Buy on Ascendis Pharma (ASND) (Insider Monkey)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-14-25 01:16AM	Morgan Stanley Remains Bullish on Ascendis Pharma (ASND) (Insider Monkey)
Sep-02-25 04:01PM	Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 (GlobeNewswire)
Aug-28-25 04:01PM	Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-12-25 10:56AM	Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players (GlobeNewswire)
Aug-07-25 04:01PM	Ascendis Pharma Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 04:01PM	Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 (GlobeNewswire)
Jul-28-25 07:00AM	FDA Approves SKYTROFA (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency (GlobeNewswire)
Jul-24-25 11:47PM	Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment (Insider Monkey)
Jul-22-25 10:50AM	Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments (GlobeNewswire)
Jul-16-25 09:55AM	Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade (Zacks)
Jul-14-25 04:01PM	New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life (GlobeNewswire)
Jul-07-25 04:01PM	Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025 (GlobeNewswire)
Jun-24-25 04:25AM	Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook (Insider Monkey)
Jun-14-25 08:40AM	Ascendis Pharma price target raised to $224 from $215 at Oppenheimer (TipRanks)
Jun-11-25 07:43PM	TransCon hGH Boosts TransCon CNP Results in Kids with Achondroplasia by Week 26 (Insider Monkey)
Jun-10-25 10:39AM	Ascendis reports interim analysis outcomes from achondroplasia trial (Clinical Trials Arena)
Jun-09-25 07:00AM	TransCon hGH Boosted Treatment Benefits of TransCon CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial (GlobeNewswire)
Jun-02-25 08:00AM	FDA Accepts TransCon CNP NDA for Priority Review (GlobeNewswire) +7.89%
May-13-25 10:13PM	Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term (Insider Monkey)
04:01PM	New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CNP (Navepegritide) (GlobeNewswire)
May-12-25 04:45PM	New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism (GlobeNewswire)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
May-06-25 08:08AM	Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1 (Insider Monkey)
May-05-25 08:30AM	Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 (GlobeNewswire)
May-02-25 03:17AM	Ascendis Pharma AS (ASND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... (GuruFocus.com)
May-01-25 09:35PM	Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:01PM	Ascendis Pharma Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-24-25 04:01PM	Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 (GlobeNewswire)
01:15AM	Artisan Mid Cap Fund Q1 2025 Commentary (Seeking Alpha)
Apr-17-25 11:00AM	Reddit initiated, Target downgraded: Wall Streets top analyst calls (TipRanks)
Apr-16-25 09:40AM	Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? (Zacks)
Apr-14-25 04:38PM	Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (Seeking Alpha)
02:03PM	Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires? (Insider Monkey)
Mar-31-25 04:01PM	Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia (GlobeNewswire)
Mar-18-25 09:49AM	Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks)
Feb-24-25 04:01PM	Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-14-25 12:00AM	Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ... (GuruFocus.com)
Feb-13-25 02:40PM	Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? (Benzinga) +12.96%
Feb-12-25 04:05PM	Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs (GlobeNewswire) +5.55%
04:01PM	Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

PresidentMr. Jan Moller Mikkelsen

CFOMr. Scott T. Smith

Executive VPMs. Pedersen Anni Lotte Kirstine Sonderbjerg

Executive VPMr. Michael Wolff Jensen L.L.M.

Senior VPMr. Mads Bodenhoff

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	May 26 '26	Buy	237.80	400	95,120	400	May 27 04:05 PM
JENSEN FLEMMING STEEN	See Remarks	May 11 '26	Sale	238.49	19,460	4,641,021	0	May 12 04:08 PM
JENSEN FLEMMING STEEN	Officer	May 11 '26	Proposed Sale	238.49	19,460	4,641,022		May 11 03:36 PM
SINGEL STINA	Officer	Mar 09 '26	Proposed Sale	240.00	3,782	907,680		Mar 09 05:30 PM
Bodenhoff Mads	Officer	Mar 06 '26	Proposed Sale	237.53	10,000	2,375,308		Mar 06 04:21 PM
Shu Aimee	Officer	Mar 05 '26	Proposed Sale	235.81	5,583	1,316,555		Mar 05 05:20 PM
SMITH SCOTT THOMAS	Officer	Mar 05 '26	Proposed Sale	240.00	10,000	2,400,000		Mar 05 05:07 PM
Jan Moller Mikkelsen	CEO	Mar 05 '26	Proposed Sale	241.38	94,000	22,689,720		Mar 05 05:04 PM
Morrison Lisa	Officer	Mar 04 '26	Proposed Sale	236.34	10,105	2,388,195		Mar 04 04:58 PM
Shu Aimee	Officer	Mar 04 '26	Proposed Sale	239.22	7,290	1,743,914		Mar 04 10:54 AM
Fairey William	Director	Mar 02 '26	Proposed Sale	242.09	1,800	435,762		Mar 02 05:01 PM
IMANI SIHAM	Director	Mar 02 '26	Proposed Sale	242.09	1,800	435,762		Mar 02 04:59 PM
SMITH SCOTT THOMAS	Officer	Mar 02 '26	Proposed Sale	242.09	18,349	4,442,109		Mar 02 04:56 PM
JENSEN MICHAEL WOLFF	Officer	Mar 02 '26	Proposed Sale	242.09	18,349	4,442,109		Mar 02 04:52 PM
Bodenhoff Mads	Officer	Mar 02 '26	Proposed Sale	242.09	6,872	1,663,642		Mar 02 04:44 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Mar 02 '26	Proposed Sale	242.09	10,800	2,614,572		Mar 02 04:40 PM
Morrison Lisa	Director	Mar 02 '26	Proposed Sale	242.09	2,100	508,389		Mar 02 04:35 PM
HOLTUG LARS	Director	Mar 02 '26	Proposed Sale	242.09	2,100	508,389		Mar 02 04:32 PM
SPROGOE KENNETT	Officer	Mar 02 '26	Proposed Sale	242.09	10,800	2,614,572		Mar 02 04:27 PM
JENSEN FLEMMING STEEN	Officer	Mar 02 '26	Proposed Sale	242.09	10,800	2,614,572		Mar 02 04:23 PM
Cha Albert	Director	Mar 02 '26	Proposed Sale	242.09	2,100	508,389		Mar 02 04:18 PM
MIKKELSEN JAN MOLLER	Officer	Jan 13 '26	Proposed Sale	211.99	86,860	18,413,631		Jan 13 02:01 PM
JENSEN MICHAEL WOLFF	Officer	Dec 04 '25	Proposed Sale	208.10	10,000	2,081,019		Dec 04 05:07 PM
Jan Moller Mikkelsen	CEO	Dec 02 '25	Proposed Sale	210.85	100,000	21,085,000		Dec 02 05:04 PM
SPROGOE KENNETT	Officer	Dec 02 '25	Proposed Sale	209.32	10,000	2,093,222		Dec 02 04:54 PM
JENSEN FLEMMING STEEN	Officer	Dec 02 '25	Proposed Sale	205.85	10,000	2,058,454		Dec 02 04:43 PM
SINGEL STINA	Officer	Dec 01 '25	Proposed Sale	209.54	218	45,680		Dec 01 02:30 PM
JENSEN FLEMMING STEEN	Officer	Sep 09 '25	Proposed Sale	203.70	5,000	1,018,503		Sep 09 04:12 PM
JENSEN MICHAEL WOLFF	Officer	Aug 29 '25	Proposed Sale	193.00	5,000	965,000		Aug 29 04:00 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Aug 27 '25	Proposed Sale	193.94	3,036	588,814		Aug 27 04:06 PM
Jan Moller Mikkelsen	President and Chief Executive	Aug 20 '25	Proposed Sale	192.79	3,000	578,385		Aug 20 05:34 PM
JENSEN MICHAEL WOLFF	Officer	Aug 15 '25	Proposed Sale	194.82	9,375	1,826,403		Aug 15 04:15 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Aug 14 '25	Proposed Sale	191.60	25,000	4,789,998		Aug 14 04:13 PM
JENSEN FLEMMING STEEN	Officer	Aug 13 '25	Proposed Sale	191.32	10,000	1,913,225		Aug 13 05:18 PM
Morrison Lisa	Director	Aug 13 '25	Proposed Sale	191.07	2,158	412,319		Aug 13 04:22 PM
SMITH SCOTT THOMAS	Officer	Aug 12 '25	Proposed Sale	192.57	10,000	1,925,734		Aug 12 05:01 PM

Open in Screener

KROS

Keros Therapeutics Inc

May 29 • 04:00PM ET

11.25

-0.14 -1.23 %

Healthcare • Biotechnology • USA • Micro • NASD

KROS Keros Therapeutics Inc daily Stock Chart

Peers: MIST MDWD NKTX OBIO RNAC ARCT HRTX VYGR FENC SLGL

| Held by: IWM VTI IWN VXF VTWO BSVO IBB SCHA DFSV AVUV

Index	RUT	P/E	-	EPS (ttm)	-3.01	Insider Own	7.96%	Shs Outstand	19.73M	Perf Week	0.27%
Market Cap	222.66M	Forward P/E	-	EPS next Y	-5.89	Insider Trans	-1.03%	Shs Float	18.22M	Perf Month	1.35%
Enterprise Value	-42.53M	PEG	-	EPS next Q	-1.43	Inst Own	90.69%	Short Float	9.35%	Perf Quarter	-20.72%
Income	-85.14M	P/S	6.71	EPS this Y	-366.83%	Inst Trans	-12.51%	Short Ratio	3.98	Perf Half Y	-35.05%
Sales	33.18M	P/B	0.78	EPS next Y	4.03%	ROA	-15.53%	Short Interest	1.70M	Perf YTD	-44.74%
Book/sh	14.47	P/C	0.79	EPS next 5Y	-	ROE	-16.79%	52W High	22.55 -50.11%	Perf Year	-19.76%
Cash/sh	14.22	P/FCF	-	EPS past 3/5Y	- -	ROIC	-28.43%	52W Low	9.79 14.91%	Perf 3Y	-77.11%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	95.27%	Volatility	3.99% 5.62%	Perf 5Y	-79.38%
Dividend TTM	-	EV/Sales	-1.28	EPS Y/Y TTM	-1998.74%	Oper. Margin	-332.30%	ATR (14)	0.60	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.62	Sales Y/Y TTM	-84.55%	Profit Margin	-256.60%	RSI (14)	48.93	Recom	1.86
Dividend Gr. 3/5Y	- -	Current Ratio	22.62	EPS Q/Q	-133.37%	SMA20	-0.55%	Beta	0.95	Target Price	22.20
Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	-99.83%	SMA50	-1.18%	Rel Volume	0.38	Prev Close	11.39
Employees	78	LT Debt/Eq	0.05	Earnings	May 14 BMO	SMA200	-26.42%	Avg Volume	428.36K	Price	11.25
IPO	Apr 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.29% -80.97%	Trades		Volume	162,789	Change	-1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$26
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral	$18
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral	$15
Dec-16-24	Reiterated	Oppenheimer	Outperform	$102 → $63
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-13-24	Reiterated	H.C. Wainwright	Buy	$100 → $47
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy	$96
Jun-25-24	Initiated	Oppenheimer	Outperform	$102
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight	$60
Jul-31-23	Initiated	Wedbush	Outperform	$86
Jul-26-23	Initiated	BofA Securities	Buy	$65
Feb-14-23	Initiated	Cowen	Outperform

Show Previous Ratings

May-14-26 08:00AM	Keros Therapeutics Reports Recent First Quarter 2026 Financial Results (GlobeNewswire) -8.34%
Mar-09-26 08:00AM	Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
08:00AM	Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS (GlobeNewswire)
Mar-06-26 11:57AM	Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? (Zacks)
Mar-05-26 12:53PM	Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? (Zacks) -14.96%
05:10PM	Loading…
Mar-04-26 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-28-26 12:35PM	Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference (MarketBeat)
Feb-26-26 04:01PM	Keros Therapeutics Appoints Charles Newton to its Board of Directors (GlobeNewswire) -5.59%
Feb-18-26 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-03-26 11:39AM	Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results? (Zacks)
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-26-26 09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
07:18AM	Loading…
Jan-23-26 07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
Jan-21-26 08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks)
09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 09:32AM	INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced (Zacks)
Jan-08-26 12:33PM	GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies (Zacks)
Jan-02-26 12:41PM	This Health Name Gains Over 400% In 2025. A Gold Stock Is Right Behind It. (Investor's Business Daily) -8.94%
04:32AM	Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics (Zacks)
07:33AM	Loading…
Dec-31-25 07:33AM	5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close (Zacks)
Dec-30-25 11:40AM	KROS or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Dec-22-25 12:00PM	Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why (Zacks) +5.33%
09:55AM	Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
04:02AM	Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros (Zacks)
Dec-15-25 09:14AM	Buy These 5 Best Value Stocks to Boost Your Portfolio in December (Zacks)
Dec-12-25 12:00PM	What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? (Zacks)
11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Nov-28-25 09:53AM	Buy These 5 Best Value Stocks to Make the Most of P/B Ratio (Zacks)
Nov-26-25 11:40AM	KROS or NVZMY: Which Is the Better Value Stock Right Now? (Zacks)
09:55AM	How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% (Zacks)
Nov-20-25 04:01PM	Keros Therapeutics Announces Final Results of Tender Offer (GlobeNewswire)
Nov-19-25 06:00AM	Keros Therapeutics Announces Preliminary Results of Tender Offer (GlobeNewswire)
Nov-13-25 07:34AM	5 Undervalued Stocks That Are Poised for Growth in November (Zacks)
Nov-10-25 11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks) +5.19%
09:55AM	Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? (Zacks)
Nov-05-25 05:40PM	Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-21-25 09:43AM	Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Oct-20-25 06:00AM	Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares (GlobeNewswire) +9.83%
Oct-15-25 06:30AM	Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital (GlobeNewswire)
Sep-08-25 08:00AM	Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting (GlobeNewswire)
Aug-28-25 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-21-25 08:30AM	ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment (PR Newswire) +6.61%
06:56AM	Keros gains FDA orphan drug status for DMD treatment KER-065 (Pharmaceutical Technology)
Aug-20-25 09:48AM	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-06-25 05:45PM	Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.29%
04:15PM	Keros to Exclusively Prioritize the Clinical Advancement of KER-065 (GlobeNewswire)
04:01PM	Keros Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 11:40AM	KROS vs. EXAS: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-23-25 10:54AM	Will Reblozyl Enable BMY to Offset the Impact of Generic Competition? (Zacks) +5.10%
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks)
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 08:00AM	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept (GlobeNewswire)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
Jun-11-25 09:40AM	McDonalds downgraded on GLP-1 drug worries: Wall Streets top analyst calls (TipRanks)
Jun-10-25 02:37PM	Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst (Benzinga)
Jun-09-25 03:12PM	ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal (PR Newswire) -6.32%
06:55AM	Keros Announces Return of $375 Million in Excess Capital to Stockholders (GlobeNewswire)
Jun-06-25 04:01PM	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 06:36AM	Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC (BioPharma Dive)
May-29-25 11:24PM	Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial (Insider Monkey)
12:54PM	Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% (Benzinga)
06:55AM	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring (GlobeNewswire)
May-27-25 01:45PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees (GlobeNewswire)
May-21-25 08:00AM	ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
May-19-25 08:00AM	Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value (GlobeNewswire)
May-12-25 12:11PM	ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
08:00AM	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:31PM	Keros Reinforces Commitment to Maximizing Stockholder Value (GlobeNewswire)
02:10PM	ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders (PR Newswire)
May-06-25 07:10PM	Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates (Zacks) -5.46%
04:01PM	Keros Therapeutics Reports Recent First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-25 08:40AM	Implied Volatility Surging for Keros Therapeutics Stock Options (Zacks)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
12:05PM	Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz (TipRanks)
11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
Apr-10-25 12:58PM	Keros Therapeutics considers sale amid investor pressure (Pharmaceutical Technology) +18.49%
06:00AM	Keros Therapeutics Announces Review of Strategic Alternatives (GlobeNewswire)
Mar-31-25 06:00AM	Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers (GlobeNewswire) -5.56%
Mar-21-25 09:55AM	Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet (Zacks)
Mar-05-25 09:55AM	Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade (Zacks)
Feb-28-25 05:00PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Feb-26-25 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-30-25 08:00AM	Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-22-25 08:53AM	Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks)

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

PresidentDr. Jasbir S. Seehra Ph.D.

Chief Financial OfficerMr. Keith C. Regnante MBA

Chief Legal Officer & SecretaryMs. Esther Cho J.D.

Chief Scientific OfficerDr. Lorena Lerner Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	May 15 '26	Buy	10.58	1,000	10,580	9,450	May 19 04:15 PM
BIENAIME JEAN JACQUES	Director	Apr 15 '26	Buy	11.70	1,000	11,700	8,450	Apr 17 04:15 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Apr 02 '26	Option Exercise	0.30	55,000	16,500	440,708	Apr 06 04:15 PM
OrbiMed Genesis Master Fund, L	Shareholder	Mar 31 '26	Proposed Sale	11.04	45,057	497,429		Mar 31 09:57 PM
BIENAIME JEAN JACQUES	Director	Mar 09 '26	Buy	11.21	2,000	22,420	7,450	Mar 11 04:33 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Feb 19 '26	Sale	16.17	7,015	113,433	385,708	Feb 20 04:15 PM
Lerner Lorena Raquel	Chief Science Officer	Feb 18 '26	Sale	16.35	3,873	63,324	31,127	Feb 20 04:15 PM
Cho Esther	SVP, General Counsel	Feb 18 '26	Sale	16.35	4,745	77,581	39,755	Feb 20 04:15 PM
Regnante Keith	CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	16.35	4,739	77,483	39,261	Feb 20 04:15 PM
Pontifax Management 4 G.P. (20	10% Owner	Oct 15 '25	Sale	17.75	4,787,331	84,975,125	0	Oct 17 05:53 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 15 '25	Sale	17.75	5,389,264	95,659,436	0	Oct 15 01:24 PM
Rovaldi Christopher	Affiliate	Sep 12 '25	Proposed Sale	15.71	85,306	1,340,157		Sep 12 04:45 PM

Open in Screener

IMNM

Immunome Inc

May 29 • 04:00PM ET

21.83

-0.71 -3.15 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: TNGX CGON KYMR NUVL INCY RYTM APGE KRYS AXSM BMRN

| Held by: XBI VTI IWM VXF IWO VTWO SCHA CANC VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.38	Insider Own	9.32%	Shs Outstand	113.17M	Perf Week	-4.92%
Market Cap	2.47B	Forward P/E	-	EPS next Y	-2.13	Insider Trans	-3.84%	Shs Float	102.69M	Perf Month	-4.88%
Enterprise Value	1.89B	PEG	-	EPS next Q	-0.52	Inst Own	104.01%	Short Float	17.17%	Perf Quarter	-0.14%
Income	-224.59M	P/S	616.52	EPS this Y	11.83%	Inst Trans	5.56%	Short Ratio	14.88	Perf Half Y	19.29%
Sales	4.01M	P/B	4.20	EPS next Y	0.36%	ROA	-46.67%	Short Interest	17.63M	Perf YTD	1.63%
Book/sh	5.20	P/C	4.24	EPS next 5Y	22.82%	ROE	-50.14%	52W High	27.65 -21.05%	Perf Year	143.91%
Cash/sh	5.15	P/FCF	-	EPS past 3/5Y	7.72% -7.71%	ROIC	-37.91%	52W Low	7.96 174.25%	Perf 3Y	326.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	25.73%	Volatility	5.14% 5.61%	Perf 5Y	4.35%
Dividend TTM	-	EV/Sales	472.13	EPS Y/Y TTM	25.39%	Oper. Margin	-5698.83%	ATR (14)	1.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	21.68	Sales Y/Y TTM	-63.29%	Profit Margin	-5593.85%	RSI (14)	48.17	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	21.68	EPS Q/Q	9.25%	SMA20	-1.21%	Beta	2.06	Target Price	35.36
Payout	-	Debt/Eq	0.01	Sales Q/Q	-100.00%	SMA50	-1.38%	Rel Volume	1.25	Prev Close	22.54
Employees	177	LT Debt/Eq	0.01	Earnings	May 12 AMC	SMA200	16.63%	Avg Volume	1.18M	Price	21.83
IPO	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.70% -100.00%	Trades		Volume	1,476,628	Change	-3.15%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-26	Initiated	Barclays	Overweight	$36
Feb-12-26	Initiated	H.C. Wainwright	Buy	$40
Dec-01-25	Initiated	Truist	Buy	$36
Sep-22-25	Initiated	Goldman	Buy	$26
Sep-05-25	Initiated	Craig Hallum	Buy	$26
Apr-02-25	Initiated	Lake Street	Buy	$23
Nov-08-24	Initiated	Stephens	Overweight	$30
May-31-24	Initiated	Piper Sandler	Overweight	$27
Apr-30-24	Initiated	JP Morgan	Overweight	$24
Apr-15-24	Initiated	Guggenheim	Buy	$35
Jan-29-24	Initiated	Leerink Partners	Outperform	$30
Dec-19-23	Initiated	Wedbush	Outperform	$12
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight	$35

Show Previous Ratings

May-30-26 08:00AM	Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting (Business Wire)
May-28-26 11:26AM	Barclays initiates oncology-focused biotechs with positive outlook (Investing.com)
May-27-26 08:00AM	Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-12-26 04:02PM	Immunome Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
May-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:30AM	Loading…
Apr-29-26 07:30AM	Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors (Business Wire)
Apr-21-26 10:30AM	Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting (Business Wire)
Apr-02-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.97%
Mar-03-26 04:02PM	Immunome Reports Full Year 2025 Financial Results and Provides Business Update (Business Wire)
Mar-02-26 02:57AM	Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development (Insider Monkey)
Feb-23-26 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 11:03PM	Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses (MarketBeat)
Feb-12-26 09:44AM	Shopify upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More (24/7 Wall St.)
04:00PM	Loading…
Feb-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.13%
Feb-04-26 08:00AM	Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire)
Jan-15-26 11:35AM	Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? (Insider Monkey) +10.07%
Jan-08-26 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:45AM	Jim Cramer on Immunome: "If You Want to Speculate on It, Fine" (Insider Monkey)
Jan-06-26 08:00AM	Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-05-26 08:05PM	Lightning Round: Nokia is up against a lot of tough companies, says Jim Cramer (CNBC TV) -5.33%
Dec-16-25 08:16PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire) -15.76%
07:26AM	Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win (Clinical Trials Arena)
Dec-15-25 06:03PM	Why Immunome Stock Surged Today (Motley Fool) +15.69%
04:36PM	Stocks Fall Ahead of US November Payroll Report (Barchart)
04:34PM	Immunome, A Top 3% Stock, Just Delivered A 'Knockout' To Merck KGaA (Investor's Business Daily)
04:01PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
12:53PM	Stock Market Today: Russell 2000, Nasdaq Decline After Strong Start to Trading Week (TheStreet)
07:00AM	Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
04:00PM	Loading…
Dec-14-25 04:00PM	Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
Dec-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-25-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire)
Nov-06-25 04:05PM	Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.35%
Oct-31-25 11:51AM	Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference (Business Wire)
Oct-23-25 12:00PM	Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance (Business Wire)
Oct-02-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.93%
Sep-25-25 06:30AM	Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) -9.33%
Sep-18-25 08:00AM	Infinimmune Announces Research Collaboration with Immunome (Business Wire) +9.57%
Sep-04-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.35%
Sep-03-25 08:00AM	Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) +10.45%
Aug-22-25 09:35AM	Gap downgraded, Ulta upgraded: Wall Street's top analyst calls (The Fly)
Aug-06-25 05:45PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.64%
05:30PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire)
Aug-05-25 05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-01-25 05:51PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks) -8.98%
Jun-16-25 12:00PM	Immunome (IMNM) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-12-25 09:55AM	Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? (Zacks)
Jun-05-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-26-25 09:55AM	Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet (Zacks)
May-22-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire) +6.82%
May-13-25 12:00PM	All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.43%
05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Immunome Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-08-25 09:55AM	Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade (Zacks)
May-02-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 06:06AM	Immunome: Transformed Pipeline Offers Multiple Catalysts (Seeking Alpha) +10.32%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Apr-04-25 08:00AM	Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Mar-26-25 08:00PM	Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement (TipRanks)
Mar-19-25 05:35PM	Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immunome Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-10-25 07:41AM	Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC (Business Wire) -5.25%
Mar-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-25 08:00AM	Immunome to Present at Upcoming March Conferences (Business Wire)
Feb-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-31-25 04:01PM	Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire) -6.44%
Jan-29-25 11:11PM	Immunome Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +12.41%
04:27PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-13-25 08:00AM	Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.28%
Jan-07-25 08:00AM	Hummingbird Bioscience Licenses Novel Antibodies to Immunome (GlobeNewswire)
Jan-02-25 06:03PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.03%
Dec-02-24 06:26PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-24 01:22PM	Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More (Insider Monkey) +16.83%
08:00AM	Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-13-24 05:15PM	Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.21%
04:05PM	Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-05-24 08:00AM	Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Nov-01-24 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.53%
Oct-30-24 08:30AM	Immunome Advances with Strategic Asset Acquisition and Agreement (TipRanks)
Oct-29-24 08:00AM	Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 (Business Wire)
Oct-18-24 08:00AM	Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium (Business Wire)
Oct-08-24 08:05AM	Immunome Appoints Roee Shahar as Executive Vice President, Commercial (Business Wire)
08:00AM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 07:00AM	Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (Business Wire) +8.57%
Aug-29-24 08:00AM	Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 03:26PM	Immunome Stock Sees RS Rating Jump To 91 (Investor's Business Daily) +6.36%
Aug-12-24 05:15PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.04%
04:01PM	Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 08:00AM	Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities (Business Wire) +5.67%
07:30AM	Nectin Therapeutics Licenses Novel Antibodies to Immunome (PR Newswire)
Jul-09-24 07:00AM	STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors (GlobeNewswire)

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

ChairmanDr. Clay B. Siegall Ph.D.

Chief Financial OfficerMr. Max Rosett

Chief Medical OfficerDr. Robert J. Lechleider M.D.

Chief Technical OfficerDr. Philip Tsai

Chief Scientific OfficerDr. Jack Higgins Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	May 15 '26	Buy	20.70	5,000	103,500	43,415	May 19 07:56 AM
Higgins Jack	Chief Scientific Officer	Apr 02 '26	Sale	21.64	9,438	204,238	22,000	Apr 03 07:48 PM
Rosett Max	Chief Financial Officer	Apr 02 '26	Option Exercise	1.22	71,561	87,053	119,037	Apr 03 07:46 PM
Rosett Max	Chief Financial Officer	Apr 02 '26	Sale	21.92	65,000	1,424,916	54,037	Apr 03 07:46 PM
Rosett Max	Officer	Apr 02 '26	Proposed Sale	72.67	65,000	4,723,550		Apr 02 11:46 AM
Higgins Jack	Officer	Apr 02 '26	Proposed Sale	21.64	9,438	204,238		Apr 02 11:32 AM
SIEGALL CLAY B	President and CEO	Mar 27 '26	Buy	19.67	25,450	500,602	690,704	Mar 31 07:11 AM
WAGENHEIM PHILIP	Director	Mar 20 '26	Sale	20.47	36,800	753,296	369,347	Mar 23 09:23 PM
WAGENHEIM PHILIP	Director	Mar 23 '26	Sale	20.65	28,200	582,330	341,147	Mar 23 09:23 PM
WAGENHEIM PHILIP	Director	Mar 20 '26	Proposed Sale	20.81	65,000	1,352,640		Mar 20 12:56 PM
BIENAIME JEAN JACQUES	Director	Mar 10 '26	Buy	22.12	1,000	22,120	37,415	Mar 12 06:05 AM
BIENAIME JEAN JACQUES	Director	Mar 11 '26	Buy	21.55	1,000	21,550	38,415	Mar 12 06:05 AM
SIEGALL CLAY B	President and CEO	Dec 30 '25	Buy	21.15	4,729	100,018	665,254	Dec 30 06:47 PM
Barchas Isaac	Director	Dec 22 '25	Sale	21.74	383,200	8,330,080	2,031,181	Dec 23 04:41 PM
SIEGALL CLAY B	President and CEO	Dec 19 '25	Buy	20.48	7,278	149,053	860,525	Dec 22 07:38 AM
Tsai Philip	Chief Technical Officer	Dec 19 '25	Buy	20.49	10,000	204,900	43,300	Dec 22 07:32 AM
SIEGALL CLAY B	President and CEO	Dec 18 '25	Buy	21.50	46,511	999,986	853,247	Dec 18 05:03 PM
Higgins Jack	Chief Scientific Officer	Sep 10 '25	Option Exercise	1.35	22,000	29,700	40,729	Sep 11 09:04 PM
BIENAIME JEAN JACQUES	Director	Jun 03 '25	Buy	9.38	5,000	46,900	36,415	Jun 03 09:21 PM

ASND

Ascendis Pharma A/S

KROS

Keros Therapeutics Inc

IMNM

Immunome Inc

Upgrade your Finviz experience